Full Title: Comparative analyses of metabolic pathways in mycobacteria: Insights into the identification and characterisation of new drug targets in M. tuberculosis, M. leprae and M. abscessus Abstract Three related mycobacteria are the cause of widespread infections in man and are the focus of intense research and drug-discovery efforts in the face of growing antimicrobial resistance.
Introduction
Pathogenic mycobacteria, such as M. tuberculosis, the causative agent of tuberculosis in humans, and M. leprae, the causative agent of leprosy, have developed complex metabolic features that enable them to explore their hosts' environments and compete with the host for nutrients. While M. leprae evolved by substantially reducing the size of its genome, losing many metabolic pathways and undergoing further pseudogenization (1, 2) , M. tuberculosis retained metabolic redundancy and an ability to use many different types of sources for nitrogen, carbon and energy, such as sugars, host-derived fatty acids, glucose, tricarboxylic acids, amino acids and cholesterol (3) . However, during infection it mostly relies on hostderived fatty acids as the primary energy source (3) . M. abscessus , a mycobacterium that causes opportunistic infections in cystic fibrosis patients, has developed numerous evolutionary metabolic adaptations (4) (5) (6) .
Metabolism refers to the chemical reactions organised into pathways and occurring in the cells of all living organisms. These pathways are broadly classified in two main categories: anabolic and catabolic, and are specialised to enable cell survival and replication. Comparative analyses of metabolism in mycobacteria can highlight and identify unique metabolic features, which will be useful in disease management and drug target identification.
Catabolic pathways are energy-producing processes whereby nutrients are broken down into smaller molecules; typical examples are glycolysis, the Krebs cycle, electron transport chain, and fermentation (3, (7) (8) (9) (10) . These are ancient pathways, widely conserved in most organisms, including mycobacteria. Glycolysis and the Krebs cycle, in addition to other energy-producing processes, such as the glyoxylate, pentose phosphate pathway and the electron transport chain, are among the core energy metabolic pathways in M. tuberculosis, M. abscessus and M. leprae (11, 12) .
Anabolic pathways are biosynthetic processes comprising the energy-consuming reactions that generate the biomass of mycobacterial cells by synthesizing cellular components such as lipids, carbohydrates, amino acids, and nucleic acids (7, 8) . These pathways are specialised in mycobacteria and enable them to maintain their structural integrity amidst harsh cellular conditions such as depletion of nutrients and responses of the host immune system during infection. Examples of conserved anabolic pathways across mycobacterial species are the amino acid and nucleic acid biosynthetic pathways. Of particular note is the complex arginine pathway, with a variety of anabolic arginine genes in M. tuberculosis (13) , the lactic acid bacteria (14) and in Pseudomonas (15) . L-arginine also occurs as a source of both carbon and nitrogen in bacteria and other microorganisms (15) and the biosynthetic pathway of Larginine has been confirmed as essential to M. tuberculosis (16) .
Enzymes of the arginine biosynthetic pathway, including amino-acid acetyltransferase (ArgA) and N-acetyl-gamma-glutamyl-phosphate reductase (ArgC) in M. tuberculosis, respectively encoded by the genes, Rv2747 and Rv1652, have previously been identified as high confidence drug targets (17, 18) . ArgA catalyses the first of eight enzymatic steps in the biosynthesis of arginine from glutamate as well as being involved in the synthesis of ornithine and proline. This involves the activation and reduction of the gamma-carboxyl group in glutamate to produce glutamate-5-semialdehyde. The subsequent steps, catalysed by acetylglutamate kinase (ArgB) and ArgC, involve the phosphorylation of N-acetyl-L-glutamate to N-acetyl-L-glutamate 5-phosphate and its subsequent reduction to N-Acetyl-L-glutamyl 5phosphate. Acetylornithine aminotransferase (ArgD) catalyses the reaction from N2-acetyl-Lornithine to N-acetyl-L-glutamate 5-semialdehyde (13) .
During the second stage of arginine biosynthesis, ornithine carbamoyltransferase (ArgF) catalyses the formation of citrulline from carbamoyl phosphate, which is in turn catalysed to (N(omega)-L-arginino) succinate by argininosuccinate synthase (ArgG). L-arginine is produced from 2-(N(omega)-L-arginino) succinate in a reaction catalysed by argininosuccinate lyase (ArgH). The intermediate compound, carbamoylphosphate, also provides an alternative to the second stages of L-arginine biosynthesis via the ornithine biosynthetic pathway. Both arginine and ornithine occur as precursors in diverse arginine degradative pathways and in the biosynthesis of polyamines (19) (20) (21) . Carbamoyl phosphate is also an intermediate in the synthesis of pyrimidines that are the activated precursors of DNA and RNA and a requirement for cell growth (15) . To understand the metabolism of an organism at a system level, it is necessary to identify and reassemble its constitutive parts (metabolites, reactions and uptake processes) which can then be integrated in genomic-scale metabolic networks that taken together can simulate the normal function of a cell (26) . These metabolic reconstructions have been used in many different ways from identifying genes essential for growth and thus establishing new drug targets to modelling quantitative drug-dose responses (27, 28) . A complementary approach to predicting drug targets for mycobacteria is to elucidate the enzymes catalysing reactions that are the sole producers of a specific metabolite or the sole consumers of that metabolite, by querying the annotated genome of an organism, a process referred to as chokepoint analysis (29) . Chokepoint enzymes of mycobacterial genomes are critical to bacterial survival and represent potential drug targets from the metabolic networks of the bacteria.
In this study, we show results from comparative pathway and chokepoint analyses of M. tuberculosis, M. abscessus and M. leprae. We review essential pathways common in the three species and predict potential drug targets for infectious diseases such as leprosy and tuberculosis. We focus on the arginine biosynthetic pathway. For this, we describe comparative modelling procedures to predict the three-dimensional structures of selected enzymes that lack experimental structures, as well as druggability analyses of potential drug targets. We show how the identification and combination of chokepoint reactions within the metabolic networks can indicate essentiality vital for survival of the pathogen. We show how bringing chokepoint analysis of the reactions together with the ligand-binding ability of the enzymes catalysing them is central to the selection of targets for drug discovery.
Results

Pathway analyses
For a comparative analysis of pathways shared between M. tuberculosis H37Rv, M. abscessus and M. leprae, we used the newly reconstructed M. tuberculosis model iEKVIII (30) and the draft BioCyc pathway databases of M. abscessus and M. leprae. There were 297 pathways in M. abscessus, 212 pathways in M. tuberculosis and 135 pathways in M. leprae (S1 Table) . The larger number of metabolic pathways in M. abscessus is consistent with the fact that it is an opportunistic pathogen with a larger genome size of 5MB (31) compared to the relatively smaller genome sizes of the obligate pathogens M. tuberculosis (4MB) and M. leprae (3.3 MB). There are fewer metabolic pathways in M. leprae as it has undergone significant genomic reduction with a small genome size of 3.3 MB and has relatively poor genome annotation (32) .
We found 105 pathways in common between the three mycobacteria (M. tuberculosis, M. abscessus and M. leprae), 152 pathways shared between M. tuberculosis and M. leprae and 112 pathways shared between M. abscessus and M. leprae. The differences in the numbers of shared pathways are mainly due to differences in the number of biosynthetic and/or degradative pathways of these organisms. The loss of genes in M. leprae due to reductive evolution has resulted in fewer metabolic pathways. The species-specific metabolic pathways identified in M. tuberculosis include processes involved in cellulose binding, hydrolase activity, as well as carbohydrate and polysaccharide binding. In the case of M. abscessus, speciesspecific biological processes include an increase in the number of reactions concerned with the biosynthesis of polyamines, thiols and L-citrulline, as well as the number of membrane transport proteins. We analysed these pathways further to identify drug targets common to the three species using the chokepoint analysis algorithm (Fig 1; S1 File) .
Chokepoint analysis for the identification of drug targets
The concept of 'chokepoint reactions' was introduced by Yeh and colleagues in 2004 (29) , when they demonstrated how the metabolic network of an organism can be queried to predict potential drug targets. A chokepoint reaction of a metabolic network must not only be a reaction that is either the only consumer or the only producer of a given metabolite, but in addition, it is required that such a metabolite is not a dead-end metabolite, i.e. each chokepoint reaction should be balanced by at least one other reaction that produces or consumes that metabolite.
Chokepoint reactions are believed to be essential to the bacteria and are therefore potential drug targets. We initially analysed the three metabolic pathway databases of M. tuberculosis, M. abscessus and M. leprae for the unique reactions within the metabolic networks using the chokepoint algorithm. We excluded the chokepoint reactions found in humans and further restricted our selection to chokepoint enzymes that are present in more than one pathway in order to assess which enzymes will produce a greater impact on the metabolic network ( S2 Table) .
Of the 333 potential drug targets initially identified in M. tuberculosis, 24 targets selected for further analyses were found to be involved in more than one pathway; these include lipid metabolism, coenzyme transport and metabolism, energy production and conversion, amino acid and nucleotide transport and metabolism (Table A in S2 Table) . We postulate that potential inhibitors of targets identified in multiple pathways would have a more significant impact on the metabolic network of the bacterium than the inhibitors of a single pathway. In M. abscessus, 313 potential drug targets were initially identified and 15 were involved in more than one pathway, including cell wall and cell processes, coenzyme transport and metabolism, energy production and conversion, amino acid and nucleotide transport and metabolism; these targets were selected for further analyses (Table B in S2 Table) . Similarly, 20 potential targets of the 183 identified in M. leprae were involved in more than one pathway including lipid transport and metabolism, nucleotide transport and metabolism, cell wall/membrane/envelope transport and metabolism/amino acid transport and metabolism / coenzyme transport and metabolism and these were selected for further analyses (Table C in   S2 Table) .
Based on in vivo and in vitro essentiality patterns, we confirmed that 75% of the chokepoint enzymes are essential proteins to Mycobacterium tuberculosis. (33, 34) . Among the prioritized drug targets, 78% of the chokepoint enzymes are present in pathways shared between M. tuberculosis, M. leprae and M. abscessus; these include the biosynthesis of amino acids, such as arginine and ornithine, nucleotide transport and metabolism and pyrimidine biosynthesis (Tables A-C in S2 Tables). Here we focus on the arginine biosynthetic pathway in the M. tuberculosis network.
We performed Flux Balance Analysis (FBA) (35) on this pathway to assess the essentiality of ArgD, ArgH and other enzymes in the M. tuberculosis network. We implemented both FBA and Flux Variability Analysis (FVA) on the m7H10 medium (a growth medium of choice for cultivating M tb) using the 'biomass' reaction as the objective function and knocking out ArgD and ArgH to assess the impact on the metabolic network and to compute the minimum and maximum fluxes that the reactions can take. The maximum growth rates (h -1 ) predicted by FBA after knocking out ArgB, ArgC, ArgD and ArgH are reported in S3 Table. A maximum growth rate of zero confirms the in-silico essentiality of the target enzymes ArgD and ArgH. Moreover, FVA (35) demonstrates a zero-flux distribution of the reactions when either of these essential enzymes is absent (Fig 3) in M. tuberculosis. Our FVA results also show that ArgF, ArgG and ArgJ exhibit zero flux distribution of reactions when they are absent from the pathway, although the growth rate of the bacterium when ArgA is knocked out is the same as the wild type. Therefore, we propose that ArgB, ArgC, ArgD, ArgF, ArgG, ArgH and ArgJ represent critical enzymes for the continued growth and viability of M. tuberculosis but ArgA is not essential to the bacterium.
Comparative 3D modelling
We identified structures for ArgB, ArgC and ArgF, chokepoint enzymes present in M. tuberculosis, M. abscessus, and M. leprae that are present in the Protein Data Bank (PDB); these are listed on Tables A-C in S2 Tables. Comparative modelling techniques (36, 37) were therefore employed to predict the structures for ArgD and ArgH that are not currently available in the PDB.
ArgD: The ArgD (acetylornithine aminotransferase) protomer of M. tuberculosis was modelled using the templates 1vef (acetylornithine aminotransferase from Thermus thermophiles) with an identity of 45% and a coverage of 92% and 4adb (succinyl-ornithine transaminase from E. coli with an identity of 42% and a coverage of 96%). The overall Molprobity score of the model is 1.36 at the 98th percentile (38, 39) . Structural superimposition of the model with each of the templates 4adb and 1vef resulted in a root mean square deviation (RMSD) of 0.203Å and 0.908Å, respectively. A homodimer was then built by superimposing the protomers with each chain of the template 1vef; we have run Steepest Descent, Conjugate gradient and Modrefiner (40) (41) (42) to reduce steric clashes and to improve the quality of the models ( Fig 4A in Fig 4) .
ArgH:
The ArgH (argininosuccinate lyase) protomer was modelled using the templates 2e9f (argininosuccinate lyase from Thermus thermophilus (Identity=45% and coverage=95%)) and 1k62 (argininosuccinate lyase from human (Identity=43% and coverage=97%)). The resulting model has an overall Molprobity score of 1.44 at 96th percentile (38, 39) . Structural superimposition with the templates 1k62 gave RMSD of 0.577Å and 1.069Å with 2e9f. A homotetramer was built by superimposing the protomer with each chain of the template 2e9f and we improved the quality of the models by running Steepest Descent, Conjugate gradient and Modrefiner (40-42) ( Fig 5A in Fig 5) .
In ArgD, the pyridoxal 5'-phosphate (PLP), the co-factor in the transamination reaction binding site, is located close to the dimeric interface ( Fig 4B in Fig 4) . It is located in the active centre cleft and forms multiple interatomic interactions with the surrounding residues. The oxygen atom of the phosphate moiety of PLP forms hydrogen-bond interactions with the main chain nitrogen atom of Thr282 ( Fig 4C in Fig 4) . It also forms weak polar interactions with side chain atoms of Thr282 and Val226. The pyridine ring forms multiple proximal π interactions with other the aromatic residues in the binding site. It forms a face to edge π interaction with Phe139 and carbon-π interaction with Val226. The Fragment Hotspots Maps which specifically highlight fragment-binding sites and their corresponding pharmacophores (43) , overlapped the binding site corresponding to hydrophobic, donor and acceptor regions with a score of 17. ArgH, the L-arginine binding site is located at the interface between domains one and two ( Fig 5B in Fig 5) . Arginine interacts with the surrounding residues by the formation of a hydrogen bond with Asn111 and π interactions with Tyr320 ( Fig 5C in Fig 5) .
Sequence-structure comparisons between human and Mtb ArgD and ArgH:
A position-specific iterated BLAST (PSI-BLAST) search against the PDB of Mtb ArgD on the human proteome revealed six structural hits with sequence identities ranging from 30-36% (S4 Table) . Alignment of Mtb ArgD sequence with the structure of 2BYJ (having the highest identity with the sequence) using JOY (44) Fig 1B) .
PSI-BLAST of Mtb
ArgH with the human proteome resulted in five hits on the PDB database with sequence identity ranging from 24-43% (S5 Table) . L-Arginine in Mtb ArgH forms two hydrogen bonds, one with the sidechain oxygen atom of Asn111 and the other with sidechain nitrogen of the Lys328. It also forms hydrophobic contacts with Val114, Arg110 and Tyr320.
JOY alignment (44) was performed for Mtb ArgH and 1AOS proteins and conserved regions were highlighted ( Supp Fig 2A) . Structural superimposition of chain A of human ArgD (1AOS) with chain A of Mtb ArgH model resulted in an RMSD of 0.751Å (Supp Fig 2B) . In Mtb ArgD, three Fragment Hotspots were mapped in the binding sites for PLP, N-Acetyl-glutamate semialdehyde and glutamate (Supp Fig 3A) while in 2BYJ (Human ArgD), only one hotspot was mapped (Supp Fig 3B) at the PLP binding site that partially overlaps with that of the Mtb ArgD. Furthermore, in Mtb ArgH, three hotspots were mapped at the subunit interfaces (Supp Fig 4A) . The maps were contoured at the score of 17 indicating higher likelihood for fragment binding. Conversely, no hotspots were mapped on the human ArgH (1AOS) at the score of 17 and few apolar regions were noted at a score of 14 (Supp Fig 4B) . All the maps were at the subunit interfaces. Mishra and Surolia (45) have recently shown that ArgH undergoes conformational changes during catalysis that can influence the orientation of the substrate binding sites and subsequently the fragment binding.
The hotspots (43) and cavities (46) for ArgD were used to explore potential binding of two drugs, Amprenavir and Cochicine, to the ArgD protein and the putative interactions were investigated using a molecular docking approach. The structures of both ligands and of the pyridoxal 5' phosphate (PLP) cofactor were retrieved from Drugbank in the simplified molecular-input line-entry system (SMILES) format (47) . The SMILES strings were converted to the PDB format and their 3D structures were optimized after adding hydrogens using the UFFOptimizeMolecule function of RDKit. The resulting structures were used to generate pdbqt files, using the prepare_ligand.py script provided with MGLTools (48) .
The modelled ArgD structure was converted to pdbqt format using MGLTools, and a cubic grid box with 24 Å-long edges was manually set to loosely accommodate the PLP binding site.
Autodock VINA was used to generate up to 10 poses of each ligand (num_modes=10) within an energy range of 10 kcal/mol (energy_range=10) and the exhaustiveness was set to 40.
The Open Drug Discovery Toolkit (ODDT) was used to re-score the docked poses, using the RFScore_V3 function, trained on the PdbBind2015 dataset. To increase the robustness of the results, the above-described procedure was repeated 200 times for each ligand and the results were clustered using the "gmx cluster" program, which integrates the GROMACS package (49) . The clustering procedure was carried out with a RMSD cut-off of 0.2 nm and the docking poses were not fitted prior to the clustering, to capture translational and rotational differences.
The resulting data were analysed using the DataWarrior software (50) , which was also used to generate the scatter-plots and box-plots. The best-scoring pose of the cluster with the highest median score was selected and submitted to the PLIP web-server in order to analyse tuberculosis. Previous studies (46, 47) have shown that this pathway is particularly exploited by Pseudomonas spp., which is able to use chlorinated compounds as sole carbon sources for nutrition, and this accounts for the prevalence of Pseudomonas in recreational waters.
Therefore, we postulate that an opportunistic bacterium such as M. abscessus might be degrading dichlorobenzene as a carbon source whilst it is living in extreme conditions in the soil. We also hypothesize that the presence of a degradation pathway of dichlorobenzene in M. leprae suggests that the bacterium is able to survive in non-host environments by exploiting other carbon sources. This is consistent with previous studies (54, 55) , which showed that the presence of viable M. leprae in soil samples is suggestive of environmental reservoirs of the bacteria. The authors, therefore, provided an explanation for the occurrence of leprosy from individuals living in areas where human leprosy cases were not previously reported; this suggests that M. leprae might not really be an obligate parasite. A summary of interaction analysis carried out by PLP is shown in S6 Table and Supp Figure   7a depicts these interactions. Our results suggest that Amprenavir likely interacts with ArgD, whilst a strong interaction with Colchicine is less likely to take place (S6 Table) . On the other hand, since Colchicine is a larger and less flexible molecule, docking assays that take receptor flexibility into account could prove to be more reliable. ArgH, on the other hand, demonstrates a promiscuity of interactions and fewer binding sites.
In a previous study, Tiwari and colleagues (59) , have described ArgB and ArgJ as potential drug targets. On this study, we have evaluated all the enzymes on the arginine biosynthetic pathway, and provided:
a) The results of the chokepoint analyses (S2 Table) and abscessus, and specie-specific pathways for each mycobacterium (S1 Table) .
c) The ligand-binding ability assessment of ArgD and ArgH (Fig 4 and 5) and 
Methodology
Pathway / Chokepoint analysis / Gene Essentiality
We performed a comparative analysis of pathways in the networks of M. tuberculosis, M. abscessus and M. leprae by using the most recent reconstruction of Mycobacterium tuberculosis metabolic network (30) and the automated build of the pathway genome database for M. abscessus and M. leprae using the Pathway Tools software (60) . To determine potential drug targets, we implemented a pipeline (Fig 1) , which includes an in-house chokepoint algorithm in Python, the input of which is a metabolic network expressed in the Systems Biology Markup Language (SBML) format, and the output is a spreadsheet with the reactions that are either the only producers or the only consumers of the metabolites. Metabolites are stored in different sheets according to the number of reactions that produce and consume them, e.g. all the metabolites that are produced by 2 reactions are contained in the same sheet. The sets of reactions that are the only producers, or the only consumers, of a given metabolite are also reported by the algorithm in the same spreadsheet. It should be noted that these sets of reactions can be seen as a generalization of the classical chokepoint algorithm, i.e. if the size of the set of reactions is one, then it corresponds to a chokepoint reaction, if the size is two, then the metabolite is either produced or consumed by at most two reactions, etc.
The algorithm also offers the possibility of identifying the 'dead-end' metabolites, i.e. those for which there are no metabolic or transport reactions within the metabolic network, and which are not contained within the final biomass composition equations. Such metabolites indicate that the metabolic model is either incomplete or contains spurious pathways.
This algorithm was run on the M. tuberculosis iEKV1011 metabolic network model and compared with the BioCyc chokepoint implementation (29) on the models of M. tuberculosis, M. abscessus and M. leprae. We performed searches from literature, the database of essential genes (DEG) (33) and the Online Gene Essentiality (OGEE) (34) database to determine the in vivo and in vitro essentiality of the potential targets. We also performed Flux Balance Analysis (FBA) and Flux Variability Analysis (FVA) on the M. tuberculosis iEK1011 model (30) using the Python toolbox COBRApy (61) .
Structure modelling of selected drug targets
Comparative modelling of selected drug targets, ArgD and ArgH, chokepoint enzymes of the arginine biosynthetic pathway, which currently lack experimental structures in the PDB, was performed using an in-house modelling pipeline, Vivace (Ochoa M. et al., Skwark M. and Blundell TL. manuscript in preparation). The pipeline was built using the Ruffus (Python) (Goodstadt, 2010) architecture that performs multiple tasks to generate models with substantial quality and reliability. In the modelling process, templates were selected from TOCCATA (Ochoa Montaño B, Blundell TL, unpublished) a database of consensus profiles built from CATH v4.2.0 and SCOPe v2.07 (62, 63) based classification of protein structures (PDB files). PDBs within each profile are clustered based on sequence similarity using CD-HIT (64,65)) and structures are aligned using BATON, which was developed as a streamlined version of the in-house program COMPARER (66) . Later FUGUE (63) is employed to generate target-template alignments from different profiles and profiles with the highest Z-scores are used in the downstream process. After further optimization of the clusters by discarding templates with more than 20% difference in sequence identity to the maximum hit, the remaining templates are classified into states based on ligand binding. Different states were generated for ligand-binding and one state for apomeric structure. Models are built for each of these states using MODELLER (36) version 9.19 (37) . Druggability checks of the selected targets, such as subcellular localization, were predicted using PSORTb a database of protein subcellular localization for bacteria and archaea (68), subCELlular LOcalization predictor, CELLO (69), TB-Pred (70) . The identified target sequences were also searched against databases such as Drug Bank (target sequence collection for approved drugs) (71) and Therapeutic Target Database (TTB) (72), using default parameter settings of BLAST. The identification of significant hits in such databases is an indicator of the potential evidence of druggability of the target. AutoDock Vina was then used to investigate the potential interactions of suggested drug candidates with the proteins using a molecular docking approach (73 
